

PRODUCT MONOGRAPH

PrMAVIK®
Trandolapril Capsules
0.5 mg, 1 mg, 2 mg and 4 mg

Angiotensin-Converting Enzyme Inhibitor

BGP Pharma ULC
85 Advance Road
Etobicoke, Ontario
M8Z 2S6

Date of Preparation:
December 19, 2014

Date of Previous Revision:
November 8, 2017

Date of Revision:
September 16, 2019

Submission Control No: 227932

Mavik® is a registered trademark of Mylan Healthcare GmbH; licensed use by BGP Pharma ULC, a Mylan company.

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION.....	3
SUMMARY PRODUCT INFORMATION	3
INDICATIONS AND CLINICAL USE.....	3
CONTRAINDICATIONS	4
WARNINGS AND PRECAUTIONS.....	5
ADVERSE REACTIONS.....	11
DRUG INTERACTIONS.....	16
DOSAGE AND ADMINISTRATION	21
OVERDOSAGE	23
ACTION AND CLINICAL PHARMACOLOGY	23
STORAGE AND STABILITY.....	27
DOSAGE FORMS, COMPOSITION AND PACKAGING	27
PART II: SCIENTIFIC INFORMATION	29
PHARMACEUTICAL INFORMATION.....	29
CLINICAL TRIALS	30
DETAILED PHARMACOLOGY	32
TOXICOLOGY	35
REFERENCES	39
PART III: CONSUMER INFORMATION.....	40
PrMAVIK®.....	40

PrMAVIK®

Trandolapril Capsules

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form/Strength	Non-medicinal Ingredients
oral	capsule /0.5 mg, 1 mg, 2 mg and 4 mg	erythrosine, gelatin, iron oxides and hydroxides, lactose, maize starch, povidone, sodium lauryl sulphate, sodium stearyl fumarate, titanium dioxide.

INDICATIONS AND CLINICAL USE

MAVIK® (trandolapril) is indicated for:

- **Treatment of Mild to Moderate Essential Hypertension.** It may be used alone or in association with thiazide diuretics.

The safety and efficacy of MAVIK® in patients with renovascular hypertension has not been established, therefore its use in these conditions is not recommended.

- **Treatment Following Acute Myocardial Infarction** in clinically stable patients with left ventricular dysfunction, with or without symptoms of heart failure, to improve survival and reduce hospitalizations for heart failure.

Sufficient experience in the treatment of patients with severe heart failure [(New York Heart Association (NYHA) Class IV] immediately after myocardial infarction is not yet available.

Geriatrics (≥ 65 years of age):

Although clinical experience has not identified differences in response between the elderly (≥ 65 years) and younger patients (< 65 years), greater sensitivity of some older individuals cannot be ruled out (see **ACTION AND CLINICAL PHARMACOLOGY, Pharmacodynamics**).

Pediatrics (< 18 years of age):

The safety and effectiveness of MAVIK® in children <18 years of age have not been established. Therefore, MAVIK® is not indicated in this patient population.

CONTRAINDICATIONS

MAVIK[®] (trandolapril) is contraindicated in:

- Patients who are pregnant, planning to become pregnant or of childbearing potential who are not using adequate contraception (see **WARNINGS AND PRECAUTIONS, Special Populations, Pregnant Women**).
- Nursing women (see **WARNINGS AND PRECAUTIONS, Special Populations, Nursing Women**).
- Patients who are hypersensitive to this drug, to any other Angiotensin Converting Enzyme (ACE) inhibitor, or to any ingredient in the formulation or component of the container. For a complete listing, see **DOSAGE FORMS, COMPOSITION AND PACKAGING**.
- Patients with a history of angioedema associated with administration of an ACE inhibitor.
- Patients with hereditary/ idiopathic angioedema.
- Combination with sacubitril/valsartan due to an increased risk of angioedema. Do not initiate MAVIK[®] until at least 36 hours have elapsed following the last dose of sacubitril/valsartan. In the case of a switch from MAVIK[®] to sacubitril/valsartan, do not start sacubitril/valsartan until at least 36 hours have elapsed following the last dose of MAVIK[®]. (see **WARNINGS AND PRECAUTIONS, Immune, Angioedema and DRUG INTERACTIONS, Drug-Drug Interactions**).
- Combination with other ACE inhibitors, angiotensin receptor blockers or aliskiren-containing medicines in patients with:
 - diabetes mellitus (type 1 or type 2)
 - moderate to severe renal impairment (GFR < 60 ml/min/1.73m²)
 - hyperkalemia (> 5mMol/L) or
 - congestive heart failure who are hypotensive(see **WARNINGS AND PRECAUTIONS, Dual Blockade of the Renin-Angiotensin-Aldosterone System (RAAS); WARNINGS AND PRECAUTIONS, Renal, Renal Impairment; WARNINGS AND PRECAUTIONS, Cardiovascular, Hypotension; and DRUG INTERACTIONS, Table 3**).
- Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption (see **WARNINGS AND PRECAUTIONS, Other, Lactose**).
- Patients with hypotensive or hemodynamically unstable states.
- Patients with hemodynamically significant bilateral artery stenosis, or severe stenosis of the artery of a solitary functioning kidney (see **WARNINGS AND PRECAUTIONS, Renal**).

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

- When used in pregnancy, angiotensin converting enzyme (ACE) inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected or if the patient is planning to become pregnant, MAVIK[®] (trandolapril) should be discontinued as soon as possible (see **WARNINGS AND PRECAUTIONS, Special Populations, Pregnant Women**).

General

Ability to Operate Machinery

Depending on individual susceptibility, the patients' ability to drive a vehicle or operate machinery may be impaired, especially in the initial stages of treatment.

Cardiovascular

Hypotension

Symptomatic hypotension has occurred after administration of MAVIK[®] usually after the first or second dose or when the dose was increased. It is more likely to occur in patients who are volume and salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. In patients with ischemic heart disease or cerebrovascular disease, an excessive fall in blood pressure (BP) could result in a myocardial infarction or cerebrovascular accident (see **ADVERSE REACTIONS**). Because of the potential fall in BP in these patients, therapy with MAVIK[®] should be started under close medical supervision. Such patients should be followed closely for the first weeks of treatment and whenever the dose of MAVIK[®] is increased. In patients with severe congestive heart failure, with or without associated renal insufficiency, ACE inhibitor therapy may cause excessive hypotension and has been associated with oliguria, and/or progressive azotemia, and rarely, with acute renal failure and/or death.

If hypotension occurs, the patient should be placed in a supine position and, if necessary, receive an intravenous infusion of 0.9% sodium chloride. A transient hypotensive response is not a contraindication to further doses which can be given, usually without difficulty, once BP has increased after volume expansion. However, lower doses of MAVIK[®] and/or reduced concomitant diuretic therapy should be considered.

If hypotension develops in patients receiving treatment following acute myocardial infarction, consideration should be given to discontinuation of MAVIK[®] (see **ADVERSE REACTIONS, Clinical Trial Adverse Drug Reactions, Treatment Following Acute Myocardial Infarction**, and **DOSAGE AND ADMINISTRATION, Recommended Dose and Dosage Adjustment, Treatment Following Acute Myocardial Infarction**).

Aortic Stenosis

There is concern, on theoretical grounds, that patients with aortic stenosis might be at particular risk of decreased coronary perfusion when treated with vasodilators.

Dual Blockade of the Renin-Angiotensin-Aldosterone System (RAAS)

There is evidence that co-administration of angiotensin converting enzyme (ACE) inhibitors, such as MAVIK[®], or of angiotensin II receptor blockers (ARBs), with aliskiren increases the risk of hypotension, syncope, stroke, hyperkalemia and deterioration of renal function, including renal failure, in patients with diabetes mellitus (type 1 or type 2); moderate to severe renal impairment (GFR < 60 ml/min/1.73m²); hyperkalemia (> 5 mMol/L) and/or congestive heart failure who are hypotensive. Therefore, the use of MAVIK[®] in combination with aliskiren-containing drugs is contraindicated in these patients (see **CONTRAINDICATIONS**).

Further, co-administration of ACE inhibitors, including MAVIK[®], with other agents blocking the RAAS, such as ARBs or aliskiren-containing drugs, is generally not recommended in any patients, since such treatment has been associated with an increased incidence of severe hypotension, renal failure, and hyperkalemia. See **CONTRAINDICATIONS, DRUG INTERACTIONS**.

If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. The concomitant use of ACE inhibitors and angiotensin II receptor blockers (ARBs) in patients with diabetic nephropathy is contraindicated (see **CONTRAINDICATIONS**).

For additional information, see **DRUG INTERACTIONS**.

Ear/Nose/Throat

As with other ACE inhibitors, dry, persistent cough, which usually disappears only after withdrawal or lowering of the dose of MAVIK[®], has been reported. Such possibility should be considered as part of the differential diagnosis of cough.

Endocrine and Metabolism

Hyperkalemia and Potassium-Sparing Diuretics

Elevated serum potassium has been observed in hypertensive patients, especially those with renal dysfunction. In clinical trials, increases in serum potassium (upper limit of normal range 5.0 mmol/L) were observed in approximately 2.2% of patients treated with MAVIK[®]; in most cases these resolved despite continued therapy. Hyperkalemia was not a cause of discontinuation of therapy in any hypertensive patient. Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, the concomitant use of agents to treat hypokalemia or other drugs associated with increases in serum potassium (potassium-sparing diuretics, potassium

supplements, potassium containing salt substitutes) and/ or left ventricular dysfunction after myocardial infarction; or the concomitant use of other active substances associated with increases in serum potassium (e.g. co-trimoxazole also known as trimethoprim/sulfamethoxazole). (see **DRUG INTERACTIONS, Drug-Drug Interactions**).

Hematologic

Neutropenia/agranulocytosis

Agranulocytosis and bone marrow depression have been caused by ACE inhibitors. The risk of neutropenia appears to be dose- and type-related and is dependent on the patient's clinical status. These reactions are more frequent in patients with renal impairment, especially those with a collagen vascular disease. Current experience with MAVIK[®] shows the incidence to be rare. Periodic monitoring of white blood cell counts and protein levels in urine should be considered, especially in patients with collagen vascular disease (e.g., lupus erythematosus and scleroderma) especially associated with impaired renal function and concomitant therapy, particularly with corticosteroids and antimetabolites. It is reversible after discontinuation of the ACE inhibitor.

Hepatic/Biliary/Pancreatic

Patients with Impaired Liver Function

MAVIK[®] should be used with caution in patients with pre-existing liver abnormalities. In such patients, baseline liver function tests should be obtained before administration of the drug and response and metabolic effect should be closely monitored.

Hepatitis (hepatocellular and/or cholestatic), elevations of liver enzymes and/or serum bilirubin have occurred during therapy with ACE inhibitors in patients with or without pre-existing liver abnormalities. In most cases the changes were reversed on discontinuation of the drug.

Elevations of liver enzymes and/or serum bilirubin have been reported with MAVIK[®] (see **ADVERSE REACTIONS**). Should the patient receiving MAVIK[®] experience any unexplained symptoms, particularly during the first weeks or months of treatment, it is recommended that a full set of liver function tests and any other necessary investigations be carried out. Discontinuation of MAVIK[®] should be considered when appropriate (see **ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Hepatic Insufficiency**).

Immune

Angioedema

Angioedema has been reported in patients taking ACE inhibitors, including MAVIK[®]. Angioedema associated with laryngeal involvement may be fatal. If laryngeal stridor or angioedema of the face, tongue, or glottis occurs, MAVIK[®] should be discontinued immediately, the patient treated appropriately in accordance with accepted medical care, and carefully observed until the swelling disappears. In instances where swelling is confined to the face and

lips, the condition generally resolves without treatment. Where there is involvement of tongue, glottis, or larynx, likely to cause airway obstruction, appropriate therapy (including, but not limited to 0.3-0.5 mL of subcutaneous epinephrine solution 1:1000) should be administered promptly (see **ADVERSE REACTIONS**).

Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see **CONTRAINDICATIONS**).

The incidence of angioedema during ACE inhibition therapy has been reported to be higher in black than in non-black patients.

The risk for angioedema may be increased in patients taking a concomitant mTOR (mammalian target of rapamycin) inhibitor (e.g. sirolimus, everolimus, temsirolimus) or neutral endopeptidase (NEP) inhibitor. Caution should be used when initiating ACE inhibitor therapy in patients already taking a mTOR, or NEP inhibitor or vice versa. (see **DRUG INTERACTIONS Drug-Drug Interactions**). Do not initiate MAVIK until at least 36 hours have elapsed following the last dose of sacubitril/valsartan. In the case of a switch from MAVIK to sacubitril/valsartan, do not start sacubitril/valsartan until at least 36 hours have elapsed following the last dose of MAVIK. (see **CONTRAINDICATIONS** and **DRUG INTERACTIONS Drug-Drug Interactions**).

Intestinal angioedema has also been reported in patients treated with ACE inhibitors. These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior history of facial angioedema and C-1 esterase levels were normal. The angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain.

Anaphylactoid Reactions during Desensitization

There have been isolated reports of patients experiencing sustained life-threatening anaphylactoid reactions while receiving ACE inhibitors during desensitization treatment with hymenoptera (bees, wasps) venom. In the same patients, these reactions have been avoided when ACE inhibitors were temporarily withheld for ≥ 24 hours, but they have reappeared upon inadvertent rechallenge.

Anaphylactoid Reactions during Low-Density Lipoprotein (LDL)-Apheresis

Life-threatening anaphylactoid reactions have been noted when patients on LDL-apheresis with dextran sulfate take ACE inhibitors at the same time. These reactions were avoided by temporarily withholding ACE inhibitor therapy prior to each apheresis.

Anaphylactoid Reactions during Membrane Exposure

Anaphylactoid reactions have been reported in patients dialyzed with high-flux membranes (e.g., polyacrylonitrile [PAN]) and treated concomitantly with an ACE inhibitor. Dialysis should be stopped immediately if symptoms such as nausea, abdominal cramps, burning, angioedema, shortness of breath and severe hypotension occur. Symptoms are not relieved by antihistamines. In these patients consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agents.

Other

Lactose

This medicine contains lactose, therefore patients with rare hereditary forms of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption syndrome should not take this medicine (see **CONTRAINDICATIONS**).

Nitritoid Reactions

Gold: Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and symptomatic hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including MAVIK[®] (see **DRUG INTERACTIONS**).

Peri-Operative Considerations

The hypotensive effects of certain inhalation anesthetics may be enhanced by ACE inhibitors. In patients undergoing surgery or anesthesia with agents producing hypotension, MAVIK[®] will block angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it may be corrected by volume repletion (see **DRUG INTERACTIONS, Table 3, Inhalation anesthetics**).

Renal

Renal Impairment

As a consequence of inhibiting the renin-angiotensin-aldosterone system (RAAS), changes in renal function have been seen in susceptible individuals. In patients whose renal function may depend on the activity of the RAAS, such as patients with bilateral renal artery stenosis, unilateral renal artery stenosis to a solitary kidney, or severe congestive heart failure, treatment with agents that inhibit this system has been associated with oliguria, progressive azotemia, and rarely, acute renal failure and/or death. In susceptible patients, concomitant diuretic use may further increase risk. Proteinuria may occur particularly in patients with existing renal function impairment or on relatively high doses of ACE inhibitors.

The use of ACE inhibitors – including MAVIK[®] - with aliskiren-containing drugs is contraindicated in patients with moderate to severe renal impairment (GFR < 60 ml/min/1.73m²) (see **CONTRAINDICATIONS** and **DRUG INTERACTIONS, Table 3**).

Use of MAVIK[®] should include appropriate assessment of renal function.

Special Populations

Pregnant Women

ACE inhibitors can cause fetal and neonatal morbidity and mortality when administered to pregnant women. When pregnancy is detected or if the patient is planning to become pregnant, MAVIK[®] should be discontinued as soon as possible. MAVIK[®] is contraindicated during pregnancy (see **CONTRAINDICATIONS**).

The use of ACE inhibitors during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios has also been reported, presumably resulting from decreased fetal renal function, associated with fetal limb contractures, craniofacial deformation, and hypoplastic lung development.

Prematurity, and patent ductus arteriosus and other structural cardiac malformations, as well as neurologic malformations, have also been reported following ACE inhibitor exposure in the first trimester of pregnancy.

Infants with a history of *in utero* exposure to ACE inhibitors should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of BP and renal perfusion. Exchange transfusion or dialysis may be required as a means of reversing hypotension and/or substituting for impaired renal function; however, limited experience with those procedures has not been associated with significant clinical benefit.

It is not known if trandolapril or trandolaprilat can be removed from the body by hemodialysis.

Animal Data

In rats, there was an increased incidence of minor defects (dilation of renal pelvis and ureters) over control values at a dose of 1000 mg/kg/day. The incidence of pelvic cavitation and dilated ureters was increased with the 10 and 100 mg/kg/day dose (see **TOXICOLOGY, Reproduction and Teratology**).

In two studies without supplementation in rabbits, covering the 0.1 to 0.8 mg/kg dose range, maternal deaths were seen at all doses with a dose-related incidence. These were associated with fetal toxicity and increased fetal loss. No teratological effect was seen. Supplementation with electrolytes allowed doses of 2 to 8 mg/kg to be given: maternal toxicity was again seen, particularly at 8 mg/kg, with weight loss and abortion. No teratological effect was seen.

In cynomolgus monkeys, abortions were 3/10, 6/10, 5/11 and 7/10 at 0, 10, 50 or 250 mg/kg/day respectively, and 1/10, 4/10, 4/10 and 7/10 at 0, 5, 25 or 125 mg/kg/day, respectively, when trandolapril was given from days 20-50 of gestation. Apart from one animal with a kinked tail in the group receiving 250 mg/kg/day, no other evidence of teratological effects attributable to treatment were observed.

Nursing Women

Following administration of radio-labelled trandolapril to lactating rats, radio-labelled trandolapril or its metabolites have been detected in the milk.

The presence of concentrations of ACE inhibitor has been reported in human milk. Use of ACE inhibitors is contraindicated during breast-feeding (see **CONTRAINDICATIONS**). Alternative treatments with better established safety profiles during breastfeeding are preferable, especially while nursing a newborn or preterm infant.

Pediatrics (< 18 years of age)

The safety and effectiveness of MAVIK[®] in children <18 years of age have not been established. Therefore, MAVIK[®] is not indicated in this patient population.

Geriatrics (≥ 65 years of age)

Although clinical experience has not identified differences in response between the elderly (≥ 65 years) and younger patients (< 65 years), greater sensitivity of some older individuals cannot be ruled out (see **ACTION AND CLINICAL PHARMACOLOGY, Pharmacodynamics** and **ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Geriatrics**).

ADVERSE REACTIONS

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

Essential Hypertension

MAVIK[®] (trandolapril) was evaluated for safety in double-blind, placebo-controlled and open-label studies, which included 2581 patients with mild to moderate essential hypertension. Of these, 265 patients were ≥65 years of age. A total of 126 patients prematurely discontinued across the various trials due to adverse events (AEs). In long-term open-label trials, 1049 patients

received trandolapril therapy, of which 212 continued treatment for 24 months, 689 for ≥ 12 months, and 911 for ≥ 6 months.

Severe adverse reactions occurring in long-term clinical trials (n=1049) with doses of trandolapril ranging from 0.5-8 mg included cough (3.9%), headache (2.3%), asthenia (2.1%), dizziness (1.7%), palpitations (0.7%), hypotension (0.5%), nausea (0.5%), pruritus (0.5%), and malaise (0.5%).

One serious adverse reaction was judged to be possibly related to MAVIK[®] therapy. This involved a rapid supraventricular arrhythmia with atrial flutter which occurred in a 68 year old male patient with a known history of heart disease.

The adverse reactions (corresponding to possibly, probably or definitely related to treatment) with an incidence $\geq 1\%$ in all double-blind, placebo-controlled trials and open-label Phase 3 hypertension trials (n=2581) are shown in **Table 1**.

Table 1. Adverse Reactions by Body System (SOC) Patients Receiving Trandolapril in Phase 3 Hypertension Trials $\geq 1\%$

Placebo-Controlled Studies		
System Organ Class (SOC)	Trandolapril n= 693 (%)	Placebo n= 194 (%)
Nervous System Disorders		
Headache	2.31	0.5
Gastrointestinal Disorders		
Nausea	1.05	0
Active-Controlled and Open-Label Studies		
System Organ Class (SOC)	Trandolapril n= 1888 (%)	
Nervous System Disorders		
Headache	2.17	
Dizziness	1.59	
Respiratory, Thoracic and Mediastinal Disorders		
Cough	2.60	
General Disorders and Administration Site Conditions		
Asthenia	2.01	

Treatment Following Acute Myocardial Infarction

In a survival study in patients with left ventricular dysfunction following myocardial infarction, 876 patients randomized to trandolapril, and 873 to placebo, were treated for an average of 2 years. A total of 209 patients prematurely discontinued across the various trials due to AEs.

The most serious adverse reactions occurring more frequently with trandolapril than with placebo included dizziness (2.6%) and hypotension (1.5%). The most frequent clinical adverse reactions occurring more frequently with trandolapril than with placebo were cough, dizziness and hypotension.

The adverse reactions (corresponding to possibly, probably or definitely related to treatment) with an incidence $\geq 1\%$, occurring in a higher percentage of trandolapril-treated patients than in placebo-treated patients, are presented in **Table 2**.

Table 2. Adverse Reactions Reported With Trandolapril in Post Myocardial Infarction Patients in Study III (TRACE) That Occurred at a Frequency $\geq 1\%$

System Organ Class (SOC)	Trandolapril n= 876 (%)	Placebo n= 873 (%)
Nervous System Disorders		
Dizziness	1.9	1.4
Respiratory, Thoracic and Mediastinal Disorders		
Cough	3.9	0.9
Vascular Disorders		
Hypotension	2.1	0.6

Less Common Clinical Trial Adverse Drug Reactions (<1%)

Blood and Lymphatic System Disorders:	Anemia, leukopenia, platelet disorder, thrombocytopenia and white blood cell disorder.
Cardiac Disorders:	Angina pectoris, bradycardia, cardiac failure, myocardial infarction, myocardial ischemia, palpitations, tachycardia and ventricular tachycardia.
Congenital, Familial and Genetic Disorders:	Congenital arterial malformation and ichthyosis.
Ear and Labyrinth Disorders:	Vertigo and tinnitus.
Eye Disorders:	Abnormal vision, blepharitis, conjunctival edema, eye disorder, glaucoma* and visual disturbance.

Gastrointestinal Disorders:	Abdominal pain, constipation, diarrhea, dry mouth, dyspepsia, esophagitis*, flatulence, gastritis, gastrointestinal disorder, gastrointestinal pain, hematemesis, nausea and vomiting.
General Disorders and Administration Site Conditions:	Chest pain, fatigue, feeling abnormal, malaise, edema and edema peripheral.
Hepatobiliary Disorders:	Hepatitis and hyperbilirubinemia
Immune System Disorders:	Anaphylactoid reaction*and hypersensitivity.
Infections and Infestations:	Bronchitis, pharyngitis, upper respiratory tract infection and urinary tract infection.
Injury, Poisoning and Procedural Complications:	Injury.
Metabolism and Nutrition Disorders:	Anorexia, enzyme abnormality, gout, hypercholesterolemia, hyperglycemia, hyperlipidemia, hyponatremia and increased appetite.
Musculoskeletal and Connective Tissue Disorders:	Arthralgia, back pain, bone pain, muscle spasms, osteoarthritis and pain in extremity.
Nervous System Disorders:	Cerebrovascular accident, dysgeusia, migraine, migraine without aura, myoclonus, paresthesia, somnolence, syncope and tremor*.
Psychiatric Disorders:	Agitation, anxiety, apathy, depression, hallucination, insomnia, libido decreased and sleep disorder.
Renal and Urinary Disorders:	Azotemia, pollakiuria, polyuria and renal failure.
Reproductive System and Breast Disorders:	Erectile dysfunction.
Respiratory, Thoracic and Mediastinal Disorders:	Dyspnea, epistaxis, pharyngeal inflammation, pharyngolaryngeal pain, productive cough, respiratory disorder, upper respiratory tract congestion and upper respiratory tract inflammation.
Skin and Subcutaneous Tissue Disorders:	Acne, angioneurotic edema, dry skin, eczema, hyperhidrosis, pemphigus*, pruritus, psoriasis, rash and skin disorder.
Vascular Disorders:	Angiopathy, hot flush, hypertension, hypotension, orthostatic hypotension, peripheral vascular disorder and varicose vein.

* These adverse effects represent adverse events; not reactions.

Rare cases of angioedema affecting the face, extremities, lips, tongue, glottis and/or larynx have been reported in patients treated with ACE inhibitors, including MAVIK®.

A symptom complex has been reported which may include fever, vasculitis, myalgia, arthralgia/arthritis, a positive anti-nuclear antibody (ANA), elevated erythrocyte sedimentation rate (ESR), eosinophilia and leukocytosis. Rash, photosensitivity or other dermatologic manifestations may also occur.

Abnormal Hematologic and Clinical Chemistry Findings

Clinical Laboratory Test Findings:

Blood creatinine increased, blood alkaline phosphatase increased, blood urea increased, blood lactate dehydrogenase increased, electrocardiogram abnormal, hyperkalemia, hyperuricemia, laboratory test abnormal, liver function test abnormal (aspartate aminotransferase increased, alanine aminotransferase increased, hepatic enzymes increased, blood potassium increased, gamma-glutamyltransferase increased, lipase increased, immunoglobulin increased), platelet count decreased, transaminases increased.

Hematologic Findings:

Hematocrit decreased, and hemoglobin decreased.

Post-Market Adverse Drug Reactions

Blood and Lymphatic System Disorders:	Agranulocytosis, haemolytic anemia* and pancytopenia.
Cardiac Disorders:	Atrioventricular block, arrhythmia and cardiac arrest.
Eye Disorders:	Vision blurred* and visual impairment.
Gastrointestinal Disorders:	Abdominal pain, intestinal angioedema, ileus, nausea and pancreatitis.
General Disorders and Administration Site Conditions:	Fever.
Hepatobiliary Disorders:	Cholestasis and jaundice.
Infections and Infestations:	Glossitis*, rhinitis* and sinusitis*.
Musculoskeletal and Connective Tissue Disorders:	Myalgia.
Nervous System Disorders:	Balance disorder, cerebral hemorrhage, dizziness, syncope and transient ischemic attack.
Psychiatric disorders:	Confusional state*.
Respiratory, Thoracic and Mediastinal Disorders:	Angioedema and bronchospasm (cough).
Skin and Subcutaneous Tissue Disorders:	Alopecia, dermatitis, dermatitis psoriasiform*, erythema multiforme*, leukocytoclastic vasculitis, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria.

*Indicates ACEI inhibitors' class adverse drug reactions (ADRs)

DRUG INTERACTIONS

Drug-Drug Interactions

Table 3. Established or Potential Drug Interactions Associated with Trandolapril

Concomitant Drug	Ref	Effect	Clinical comment
Agents Increasing Serum Potassium	C	A decrease in aldosterone production and a significant increase in serum potassium could occur.	Potassium sparing diuretics such as spironolactone, triamterene or amiloride, or potassium supplements should be given only for documented hypokalemia and with caution and frequent monitoring of serum potassium. Salt substitutes which contain potassium should be used with caution.
Agents Causing Renin Release	CT	The antihypertensive effect of MAVIK® is augmented by antihypertensive agents that cause renin release (e.g., diuretics).	
Allopurinol, cytostatic, immunosuppressive agents, systemic corticosteroids or procainamide	T	Concomitant administration with ACE inhibitors may lead to an increased risk of leukopenia.	
Antidepressant	T	Combination with a neuroleptic or tricyclic antidepressant increases the risk of orthostatic hypotension.	
Antidiabetic Agents (e.g. insulin , oral hypoglycemic agents)	T	Concomitant use of antidiabetic medicines (insulin or oral hypoglycemic agents) may cause an increased blood glucose lowering effect with greater risk of hypoglycemia.	Monitor closely blood glucose.
Antacids	T	Decreased bioavailability of ACE inhibitors	It is recommended to ingest antacids and MAVIK® separately.
Cyclosporine	T	Hyperkalaemia may occur during concomitant use of ACE inhibitors with cyclosporine.	Monitoring of serum potassium is recommended.
Cimetidine	CT	No clinically significant interaction has been found between trandolaprilat and cimetidine.	

Concomitant Drug	Ref	Effect	Clinical comment
Concomitant Diuretic Therapy	CT	Patients concomitantly taking ACE inhibitors and diuretics, and especially those, in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of BP after initiation of therapy.	The possibility of adverse hypotensive effects after the first dose of trandolapril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with MAVIK®. If it is not possible to discontinue the diuretic, the starting dose of MAVIK® should be reduced and the patient should be closely observed for several hours following the initial dose until BP has stabilized (see WARNINGS AND PRECAUTIONS and DOSAGE AND ADMINISTRATION).
Co-trimoxazole (trimethoprim/sulfamethoxazole)	C	Patients taking concomitant co-trimoxazole (trimethoprim/sulfamethoxazole) may be at increased risk for hyperkalaemia (see WARNINGS AND PRECAUTIONS, Endocrine and Metabolism, Hyperkalemia and Potassium-Sparing Diuretics).	Sudden deaths have been reported in older patients receiving ACE inhibitors and co-trimoxazole concomitantly. The serum potassium concentration should be closely monitored when the concomitant therapy cannot be avoided.
Digoxin	CT	In one open-label study conducted in 8 healthy male volunteers, in which multiple therapeutic doses of both MAVIK® and digoxin were administered, no changes were found in serum levels of MAVIK®, trandolaprilat, and digoxin. Pharmacodynamically, the combination had a synergistic effect on left ventricular functions, as evidenced by the improvement in systolic time-intervals.	

Concomitant Drug	Ref	Effect	Clinical comment
Dual blockade of the Renin-Angiotensin-Aldosterone-System (RAAS) with ACE inhibitors, ARBs or aliskiren-containing drugs	CT	There is evidence that the concomitant use of ACE-inhibitors, ARBs or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure).	<p>The use of MAVIK® in combination with other ACE inhibitors, ARBs or aliskiren-containing agents is contraindicated in patients with:</p> <ul style="list-style-type: none"> •Diabetes mellitus (type 1 or type 2); •Moderate to severe kidney insufficiency (GFR < 60mL/min/1.73m²); •Hyperkalaemia (> 5mMol/l); or •Congestive heart failure who are hypotensive. <p>It is not recommended in other patients.</p> <p>See CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS, <u>Dual Blockade of the Renin-Angiotensin-Aldosterone System (RAAS); WARNINGS AND PRECAUTIONS, Renal, Renal Impairment; WARNINGS AND PRECAUTIONS, Cardiovascular, Hypotension.</u></p>
Gold	T	Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and symptomatic hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including MAVIK®.	
Heparin	T	Hyperkalaemia may occur during concomitant use of ACE inhibitors with heparin.	Monitoring of serum potassium is recommended.
Inhalation anesthetics	T	<p>The hypotensive effects of certain inhalation anesthetics may be enhanced by ACE inhibitors.</p> <p>In patients undergoing surgery or anesthesia with agents producing hypotension, MAVIK® will block angiotensin II formation secondary to compensatory renin release.</p>	If hypotension occurs and is considered to be due to this mechanism, it may be corrected by volume repletion (see WARNINGS AND PRECAUTIONS, <u>Peri-Operative Considerations.</u>
Lithium	C	Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concurrently ACE inhibitors and lithium.	Lithium based drugs should be administered with caution, and frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be further increased.

Concomitant Drug	Ref	Effect	Clinical comment
mTOR inhibitors e.g. sirolimus, everolimus, temsirolimus	C	Coadministration of ACE inhibitor and mTOR (mammalian target of rapamycin) inhibitor may increase the risk for angioedema. (see WARNINGS AND PRECAUTIONS, <u>Immune Angioedema</u>).	Caution should be used when either initiating MAVIK® in patients already taking mTOR inhibitors or <i>vice versa</i> (see WARNINGS AND PRECAUTIONS, <u>Immune, Angioedema</u>).
Neutral endopeptidase (NEP) inhibitors	C, T	Co-administration of ACE inhibitors and NEP inhibitors may increase the risk of angioedema.	Combination with ENTRESTO® (sacubitril/valsartan) is contraindicated. Caution should be used when either initiating ACE inhibitor therapy in patients already taking a neutral endopeptidase inhibitor or <i>vice versa</i> . Do not initiate MAVIK® until at least 36 hours have elapsed following the last dose of sacubitril/valsartan. In the case of a switch from MAVIK® to sacubitril/valsartan, do not start sacubitril/valsartan until at least 36 hours have elapsed following the last dose of MAVIK®. (see CONTRAINDICATIONS; WARNINGS AND PRECAUTIONS, <u>Immune, Angioedema</u>).
Nifedipine SR	CT	A study evaluating the potential pharmacokinetic and pharmacodynamic interaction between nifedipine (20 mg) (sustained release) and MAVIK® (4 mg) was conducted in 12 healthy male volunteers. After a single dose, no pharmacokinetic or pharmacodynamic interaction was found between the 2 products.	

Concomitant Drug	Ref	Effect	Clinical comment
Non-steroidal anti-inflammatory drugs (NSAIDs) including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors)	T	<p>The antihypertensive effects of ACE inhibitors may be reduced with concomitant administration of NSAIDs (including acetylsalicylic acid used in higher doses as an anti-inflammatory drug, e.g. for pain relief). As with other ACE inhibitors, the combination of MAVIK[®] with NSAIDs predisposes to a risk of hyperkalemia particularly in cases of renal failure.</p> <p>In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including MAVIK[®], may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible.</p>	<p>BP should be monitored more closely when any NSAID is added or discontinued in a patient treated with MAVIK[®].</p> <p>Monitor renal function periodically in patients receiving MAVIK[®] and NSAID therapy.</p> <p>NSAIDs including acetylsalicylic acid, unless acetylsalicylic acid is used in lower doses as a platelet aggregation inhibitor, should be avoided with ACE inhibitors in patients with heart failure.</p>
Warfarin	CT	<p>In a multi-dose, double-blind, placebo-controlled, pharmacodynamic interaction study with 20 healthy volunteers, MAVIK[®] (2 mg) was administered with therapeutic doses of warfarin. No clinically significant effects on the anticoagulant properties of warfarin were found.</p>	

Legend: C= Case Study; CT = Clinical Trial; T = Theoretical

Drug-Food Interactions

Food

Patients should be told not to use salt substitutes or foods containing potassium without consulting their physician (see **WARNINGS AND PRECAUTIONS**). Food does not affect the C_{max} and AUC of trandolapril and trandolaprilat, however food prolongs the T_{max} of trandolaprilat by approximately 2 hours.

Alcohol

Alcohol enhances the bioavailability of ACE inhibitors and therefore increases the risk of hypotension.

Drug-Herb Interactions

Interactions with herbal products have not been evaluated.

Drug-Laboratory Interactions

Interactions with laboratory tests have not been evaluated.

Drug-Lifestyle Interactions

Interactions with lifestyle have not been evaluated.

DOSAGE AND ADMINISTRATION

Dosing Considerations

Essential Hypertension

Dosage of MAVIK[®] (trandolapril) must be individualized. Initiation of therapy requires consideration of recent antihypertensive drug treatment, the extent of BP elevation and salt restriction. The dosage of other antihypertensive agents being used with MAVIK[®] may need to be adjusted. See **WARNINGS AND PRECAUTIONS**; and **DRUG INTERACTIONS**.

In some patients treated once daily, the antihypertensive effect may diminish towards the end of the dosing interval. This can be evaluated by measuring BP just prior to dosing to determine whether satisfactory control is being maintained for 24 hours. If it is not, an increase in dose should be considered. If BP is not controlled with MAVIK[®] alone, a diuretic may be added.

Diuretic-Treated Patients

Symptomatic hypotension occasionally may occur following the initial dose of MAVIK[®] and is more likely in patients who are currently being treated with a diuretic. The diuretic should, if possible, be discontinued for 2-3 days before beginning therapy with MAVIK[®] to reduce the likelihood of hypotension (see **WARNINGS AND PRECAUTIONS**). If the diuretic cannot be discontinued, an initial dose of 0.5 mg MAVIK[®] should be used with careful medical supervision for several hours and until BP has stabilized. The dosage of MAVIK[®] should subsequently be titrated to the optimal response.

Recommended Dose and Dosage Adjustment

The recommended initial dosage of MAVIK[®] is 1 mg once daily. Dosage should be adjusted according to BP response at intervals of 2-4 weeks up to a maximum of 4 mg once daily. The usual maintenance dose is 1-2 mg once daily.

Dosage in the Elderly

In elderly patients with normal renal and hepatic function, no dosage adjustment is necessary (see **WARNINGS AND PRECAUTIONS, Geriatrics**).

However, as some elderly patients may be particularly susceptible to ACE inhibitors, administration of low initial doses and evaluation of the BP response and of the renal function at the beginning of the treatment is recommended.

Dosage in Renal Impairment

Creatinine clearance <30 mL/min/1.73 m²: For patients with a creatinine clearance <30 mL/min/1.73 m², the recommended initial dose is 0.5 mg MAVIK[®] once daily. Dosage may be titrated upward until BP is controlled or to a maximum total daily dose of 1 mg.

Creatinine clearance <10 mL/min/1.73 m²: In patients with severe renal impairment (creatinine clearance <10 mL/min/1.73 m²), do not exceed a single daily dosage of 0.5 mg.

Dosage in Liver Impairment

The recommended initial dose is 0.5 mg MAVIK[®] once daily (see **WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic** and **ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Hepatic Insufficiency**).

Treatment Following Acute Myocardial Infarction

Dosage should be individualized. Initiation of therapy requires consideration of concomitant medication and baseline BP in hemodynamically stable patients.

≥3 days following acute myocardial infarction in patients with left ventricular dysfunction: Start with a dose of 1 mg MAVIK[®] once daily.

After 2 days at 1 mg once daily: Increase the dose to 2 mg once daily. For patients who cannot tolerate this dose, the 1 mg once daily dose can be maintained.

After 1 month: Increase dosage to 4 mg once daily in patients tolerating the 2 mg once daily dose. Again, for patients who cannot tolerate the 4 mg once daily dose, the 2 mg once daily dose can be maintained.

The dose must be reduced when it is clinically necessary (see **WARNINGS AND PRECAUTIONS, Cardiovascular, Hypotension**). If hypotension preventing the patient from standing or walking is observed and is not explained by other factors, the dose must be reduced.

For patients with renal or liver impairment, institute a starting dose no higher than 0.5 mg once daily.

Missed Dose

If the patient forgets to take a capsule, he should take one as soon as he remembers, if he remembers on the same day. If not, he should not take the missed capsule at all. He should wait until it is time to take the next dose. He should never double-up on a dose to make up for the one he has missed.

Administration

MAVIK[®] may be taken before, during or after meals (see **DRUG INTERACTIONS, Drug-Food Interactions**).

OVERDOSAGE

For management of a suspected drug overdose, contact your regional Poison Control Centre.

Limited data are available regarding overdosage of MAVIK[®] (trandolapril) in humans. The most likely clinical manifestation of overdosage of an ACE inhibitor such as MAVIK[®] would be symptoms attributable to severe hypotension which should normally be treated by intravenous volume expansion with normal saline. After ingestion of an overdose of trandolapril capsules, total intestinal lavage should be considered.

Blood pressure should be monitored and if hypotension develops, volume expansion should be considered. There is no specific antidote for trandolapril overdose. Symptoms expected with ACE inhibitor also include: shock, stupor, bradycardia, electrolyte disturbance and renal failure. It is not known if trandolapril or trandolaprilat can be removed from the body by hemodialysis.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

MAVIK[®] (trandolapril) is a non-sulphydryl angiotensin converting enzyme (ACE) inhibitor.

ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the pharmacologically active substance, angiotensin II, which is a vasopressor agent. In addition,

angiotensin II stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in a decreased plasma angiotensin II level. The resulting lack of negative feedback on renal renin secretion leads to an increased plasma renin activity.

ACE is identical to kininase II. Thus, trandolapril administration may interfere with the degradation of the potent peptide vasodilator bradykinin, which may contribute to the therapeutic activity of trandolapril. Trandolapril is a prodrug, which is hydrolysed to its active diacid form, trandolaprilat, a potent ACE inhibitor.

The antihypertensive effect of trandolapril is due to a reduction in peripheral vascular resistance with little or no change in cardiac output and heart rate. The decrease in BP is not accompanied by water or sodium retention. No modification was found in the urinary excretion of chloride and potassium.

Pharmacodynamics

Administration of MAVIK[®] to patients with mild to moderate essential hypertension results in a reduction of both supine and standing BP usually with little or no orthostatic change or change in heart rate. Symptomatic postural hypotension is infrequent, although this may occur in patients who are salt- and/or volume-depleted (see **WARNINGS AND PRECAUTIONS**).

In mild to moderate hypertensive patients, significant reductions in BP were seen at 2 hours, and peak antihypertensive effects were seen after approximately 8 hours. At the recommended doses, antihypertensive effects are maintained throughout the 24-hour dosing interval in most patients who responded to trandolapril. Abrupt withdrawal of MAVIK[®] has not resulted in rapid increase in BP.

Following single oral therapeutic doses in healthy male volunteers, a rapid onset of ACE inhibition was observed. The peak inhibition was reached between 2-4 hours after the initial dose.

The effectiveness of MAVIK[®] appears to be similar in the elderly (≥ 65 years of age) and younger adult patients given the same daily doses.

The antihypertensive effect of ACE inhibitors is generally lower in black patients than in non-blacks.

The antihypertensive effect of MAVIK[®] and thiazide diuretics used concurrently is greater than that seen with either drug used alone.

Pharmacokinetics

Absorption

Following a single oral administration of MAVIK[®] to healthy volunteers, trandolapril was detectable in the plasma 30 minutes later with peak concentrations reached within 1 hour. Trandolaprilat, the active metabolite, reached peak plasma concentrations after approximately

6 hours. Plasma concentrations of both trandolapril and trandolaprilat were dose dependent. While food can delay the rate of absorption of trandolapril, there is no clinically significant effect on other pharmacokinetic and pharmacodynamic parameters of trandolaprilat.

Approximately 40-60% of an administered oral dose of trandolapril is absorbed.

Distribution

Eighty percent (80%) of the circulating trandolapril and $\leq 94\%$ of the circulating trandolaprilat are bound to plasma proteins. The protein binding is not saturable for trandolapril but is saturable for trandolaprilat.

Metabolism

Trandolapril undergoes extensive first-pass metabolism in the liver, and this is the reason for its low bioavailability: 7.5% (ranging from 4-14%). In the liver it is transformed into its biologically active diacid form, trandolaprilat. Trandolaprilat itself is poorly absorbed after oral administration. Minor metabolic pathways lead to the formation of diketopiperazine derivatives of trandolapril and trandolaprilat. These molecules have no ACE inhibitory activity. Glucuronide conjugated derivatives of trandolapril and trandolaprilat are also produced.

Excretion

With once-daily dosing, a steady-state of trandolaprilat plasma concentrations is reached within 4 days in healthy male and female subjects as well as in patients with chronic renal failure. Similar results were found in young (< 65 years) as well as old (≥ 65 years) male and female patients suffering from mild to moderate essential hypertension. As is the case with several other ACE inhibitors, trandolaprilat has a polyphasic elimination profile with a slow terminal phase, probably the result of binding to ACE and a subsequently slow dissociation from the enzyme. Over the first 16-20 hours following oral administration of MAVIK[®], there is a rapid elimination phase of trandolaprilat. Beyond this time, there is a prolonged terminal elimination phase. The effective half-life ($t_{1/2}$) for accumulation of trandolaprilat has been estimated to be in the range of 16-24 hours. The accumulation ratio as measured in hypertensive patients was about 1.5. Trandolapril's elimination half-life ($t_{1/2}$) is on average 0.7 hours.

In healthy male volunteers the excretion, in urine and feces, of trandolapril following an 8 mg single oral dose of ¹⁴C-labelled drug is virtually complete after 7 days ($99.2 \pm 3.4\%$): 82% of the dose was eliminated in 48 hours and 93% of the dose in 72 hours. In this dual route of excretion, urinary and fecal recoveries accounted for 33% and 66% of the total excretion, respectively. Trandolaprilat represents 46% of the urinary and 57% of the fecal excretion. The glucuronide derivatives of trandolapril and trandolaprilat excreted represent each about 13% of total urinary excretion and, 2% and 4% of total fecal excretion. The diketopiperazine of trandolaprilat was 7% of the total urinary excretion. The amounts of trandolapril excreted unchanged and the corresponding diketopiperazine are negligible (< 0.5% of the dose).

Renal clearance of trandolaprilat varies depending on dose, as seen in **Table 4**.

Table 4. Renal Clearance of Trandolaprilat after a Single Oral Administration of Trandolapril to Healthy Subjects

Parameters	0.5 mg	1 mg	2 mg	4 mg
Trandolaprilat CL _{r0-96 h} (L/h)	0.15 ± 0.05	1.03 ± 0.18	2.02 ± 0.25	3.93 ± 0.39

Note: Trandolaprilat displays non-linear pharmacokinetics, especially at low doses.

Special Populations and Conditions

Pediatrics (<18 years of age)

Trandolapril pharmacokinetics has not been evaluated in patients <18 years of age.

Geriatrics

No data is available.

Gender

No data is available.

Race

Ethnic differences: In African American patients, ACE-inhibitors are less effective in lowering blood pressure than in Caucasian patients.

Hepatic Insufficiency

In patients with moderate to severe impairment of liver function, plasma trandolapril levels were approximately 10x higher than in healthy subjects. The plasma concentrations of trandolaprilat and the quantities excreted in the urine were also increased, although to a lesser degree. The dose should therefore be reduced in these patients (see **DOSAGE AND ADMINISTRATION**).

In one study, cirrhotic patients who received a single dose of MAVIK[®] 2 mg exhibited a 9-fold increase in trandolapril C_{max} and AUC values compared to healthy subjects. The C_{max} and AUC values of trandolaprilat were about doubled (see **DOSAGE AND ADMINISTRATION**).

Renal Insufficiency

In patients with creatinine clearance ≤ 30 mL/min/1.73m², the C_{max} and AUC of trandolaprilat were approximately doubled after repeated oral administration, as compared to those of normal subjects.

Genetic Polymorphism

No data is available.

STORAGE AND STABILITY

Store MAVIK[®] (trandolapril) between 15°-25°C in its original container. MAVIK[®] should not be stored beyond the date indicated on the container.

DOSAGE FORMS, COMPOSITION AND PACKAGING

MAVIK[®] capsules are formulated for oral administration and contain trandolapril as medicinal ingredient.

MAVIK[®] 0.5 mg capsules: red opaque body, yellow opaque cap, size no. 4 capsules.

MAVIK[®] 1.0 mg capsules: red opaque body, orange opaque cap, size no. 4 capsules.

MAVIK[®] 2.0 mg capsules: red opaque body, red opaque cap, size no. 4 capsules.

MAVIK[®] 4.0 mg capsules: red opaque body, maroon opaque cap, size no. 2 capsules.

All MAVIK[®] dosages are available in HDPE plastic bottles of 100, or blister-packs.

Medicinal Ingredients

MAVIK[®] capsules 0.5 mg, 1.0 mg, 2.0 mg and 4.0 mg contain the medicinal ingredient trandolapril in quantities of 0.5 mg, 1.0 mg, 2.0 mg and 4.0 mg, respectively.

Listing of Non-Medicinal Ingredients

Each MAVIK[®] capsule contains the following non-medicinal ingredients: lactose, maize starch, povidone and sodium stearyl fumarate (as filler and gliding agents), and empty gelatin capsules.

Empty gelatin capsules for all potencies of trandolapril are composed of gelatin NF and colouring agents specific to each potency (see **Table 5** below).

Table 5. Composition of Empty Gelatin Capsules for All Trandolapril Strengths

Potency	Cap	Body
0.5 mg	titanium dioxide, iron oxides and hydroxides, sodium lauryl sulphate	titanium dioxide, iron oxides and hydroxides, erythrosine, sodium lauryl sulphate
1.0 mg	titanium dioxide, iron oxides and hydroxides, erythrosine, sodium lauryl sulphate	titanium dioxide, iron oxides and hydroxides, erythrosine, sodium lauryl sulphate
2.0 mg	titanium dioxide, iron oxides and hydroxides, erythrosine, sodium lauryl sulphate	titanium dioxide, iron oxides and hydroxides, erythrosine, sodium lauryl sulphate
4.0 mg	titanium dioxide, iron oxide and hydroxides, erythrosine, sodium lauryl sulphate	titanium dioxide, iron oxide and hydroxides, erythrosine, sodium lauryl sulphate

PART II: SCIENTIFIC INFORMATION


PHARMACEUTICAL INFORMATION

Proper name: Trandolapril

Chemical name: (2S, 3aR, 7aS)-1-[(S)-N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]alanyl] hexahydro-2-indolinecarboxylic acid

Molecular formula and molecular mass: $C_{24}H_{34}N_2O_5$ 430.5

Structural formula:



Physicochemical properties: White crystalline powder with a melting point of approximately 125°C and a pKa=5.6. Practically insoluble in water, and freely soluble in chloroform, dichloromethane and methanol. It is free of odour with a bitter taste.

CLINICAL TRIALS

Study Demographics and Trial Design

Hypertension

Table 6. Summary of Patient Demographics for Clinical Trials in Patients with Mild to Moderate Essential Hypertension

Study #	Trial Design	Dosage, Route of Administration and Duration	Study Subjects (n=number)	Mean Age (Range)	Gender
Study I	Multicentre, randomized, double-blind, placebo-controlled	0.5, 1 or 2 mg daily Oral dose 28 days	170 Placebo: 44 Trandolapril: 126	48.2 years (17 to 72)	Male: 66 Female: 104
Study II	Multicentre, randomized, double-blind, placebo-controlled	0.25, 0.5, 1, 2 or 4 mg daily Oral dose 6 weeks	313 Placebo: 50 Trandolapril: 263	56.0 years (25 to 84)	Male: 203 Female: 110

Left Ventricular Dysfunction Following Acute Myocardial Infarction

Table 7. Summary of Patient Demographics for Study III (TRACE) in Patients with Left Ventricular Dysfunction Following Acute Myocardial Infarction

Study #	Trial Design	Dosage, Route of Administration and Duration	Study Subjects (n=number)	Mean Age (Range)	Gender
StudyIII (TRACE*)	Multicentre, randomized, double-blind, placebo-controlled	0.5 [†] , 1, 2,4 mg daily Oral dose 24 to 50 months	1749 Placebo: 873 Trandolapril: 876	67.5 years (30 to 93)	Male: 1248 Female: 501

* TRACE: TRAndolapril Cardiac Evaluation study

† An oral test dose of 0.5 mg trandolapril was given to all eligible patients prior to randomization; patients were subsequently force-titrated to 1-4 mg per day.

Study Results

Hypertension

Studies I and II compared the efficacy and tolerance of trandolapril to placebo. Trandolapril administered once daily at doses of 1 mg, 2 mg and 4 mg for 4-6 weeks was effective at lowering average trough supine diastolic blood pressure (DBP) in non-black patients with mild to moderate essential hypertension.

Left Ventricular Dysfunction Following Acute Myocardial Infarction

Table 8. Results of Study III (TRACE) Trial in Patients with Left Ventricular Dysfunction after Acute Myocardial Infarction

Primary Endpoints	Trandolapril	Placebo	p-Value
Mortality from all causes	304 (34.7%)	369 (42.3%)	p=0.001

It can be seen in **Table 8** and **Figure 1** that trandolapril provides a statistically significant reduction in death from all causes (final analysis of the intent-to-treat population).




Figure 1. Cumulative Mortality from All Causes among Patients Receiving Trandolapril or Placebo

DETAILED PHARMACOLOGY

Animal

Pharmacodynamics

Mechanism of Action

Table 9 summarizes the trandolapril mechanism of action in animal models.

Table 9. Trandolapril Mechanism of Action

Study	Species	No. of animals per group	Route	Dose	Results
Inhibition of Angiotensin I induced pressor response after oral trandolapril	Rat (Male) (Sprague Dawley)	4-9	Oral Single Dose	0.003 0.01 0.03 0.1 0.3	ID ₅₀ : trandolapril 35 mcg/kg trandolaprilat 500 mcg/kg
Inhibition of Angiotensin I induced pressor response after oral trandolapril	Dog Beagle	4	Oral	0.03 0.1 0.3 1.0	Dose dependent inhibition. At 0.3 mg/kg: 93% inhibition after 1.5 h and 29% after 6 h. At 1.0 mg/kg: 100% inhibition after 30 min and 59% after 6 h.
Effect of bilateral nephrectomy	Rat (spontaneously hypertensive)	10-11	Oral Single dose	3	The antihypertensive effect was abolished.
Effect of inhibition of prostaglandin biosynthesis (via Indomethacin 5 mg/kg p.o.)	Rat (spontaneously hypertensive)	10-11	Oral Single dose	3	The antihypertensive effect was not modified.
<i>In vitro</i> inhibition of ACE by trandolapril	Blood serum from Rat (Sprague Dawley) Dog (Beagle) Human (healthy male volunteers)	--	<i>In vitro</i>	--	Rat: IC ₅₀ = 1.67 ± 0.74 nM Dog: IC ₅₀ = 368 ± 50 nM Human: IC ₅₀ = 7.06 ± 2.11 nM

Study	Species	No. of animals per group	Route	Dose	Results
Regional and general hemodynamic effects	Rat (spontaneously hypertensive)	10	Oral	5 (for 8 days)	On day 8 systolic blood pressure (SBP) was reduced by 31% with no effect on heart rate, cardiac index and stroke volume. Total peripheral resistance was reduced by 37%. Regional vascular resistance was reduced in all territories (34-65%) whereas regional blood flow was increased in all regions explored (33-88%).
Determination of minimum effective dose	Rat (Male) (spontaneously hypertensive)	20	Oral	0.003 0.01 0.1 0.3 1.0 3.0 (for 14 days)	Dose dependent reduction in BP; ranged from 8.5-39%. Dose dependent reduction in cardiac hypertrophy ranged from 5-17%.
ACE inhibition by measurement of the potentiation of the hypotensive response to bradykinin	Rat (Sprague Dawley) (Male)	6	i.v.	0.003 0.006 0.010 0.03 1 (single dose)	ED ₅₀ = Dose yielding 50% of the maximum increase in the hypotensive response to bradykinin Trandolapril = 4.9 mg/kg Trandolaprilat = 4.1 mg/kg
ACE inhibition in the rat aorta, atrium and ventricle	Rat (Okamoto) hypertensive (Male)	7-10	Oral	0.0001 0.0003 0.001 0.003 0.01 1.0	ID ₅₀ = Dose inhibiting enzyme activity by 50% Right atrium = 0.00132 Left atrium = 0.00107 Aorta = 0.00066 Apex = 0.00798 Right ventricular wall = 0.01510 Septum = 0.00740

Effects on Blood Pressure

Table 10 summarizes the effects of trandolapril on BP in animal models.

Table 10. Effects of Trandolapril on Blood Pressure

Hypertensive Model	Species	No. of animals per group	Route	Dose (mg/kg)	Duration	Result
Antihypertensive effects in spontaneously hypertensive rats	Rat	12-22	Oral	0.3 3.0 30	Single dose	Fall in mean BP 6 h after gavage: 10%, 13% and 17% at 0.3, 3.0 and 30 mg/kg, respectively. 24 h after gavage the fall was 10%, 11% and 15% at 0.3, 3.0 and 30 mg, respectively.
Antihypertensive effect in the spontaneously hypertensive rat pre-treated with a thiazide diuretic	Rat	12-22	Oral	0.3 3.0 30	Single dose	A dose-dependent fall in mean BP of 14, 30 and 34% at doses of 0.3, 3.0 and 30 mg/kg, respectively was found. The peak effect occurred after 24 h.
Antihypertensive activity after 14 days of treatment in spontaneously hypertensive rats	Rat	11-12	Oral	3.0	14 days	Mean BP decreased by 33% after 14 days.
Antihypertensive effect on conscious normotensive dog	Dog (Male Beagle)	5-6	Oral	3.0 10	Single dose	At 3 mg/kg: DBP was reduced by 14% after 3.5-4 h post-administration. At 10 mg/kg: A decrease of 15% was observed 1.5-4 h post-administration

Pharmacokinetics

Table 11 summarizes the pharmacokinetic parameters following oral administration of trandolapril to animals and man.

Table 11. Pharmacokinetic Parameters Following Oral Administration of Trandolapril to Animals and Man

Dose (mg/kg)		Rat	Dog	Man
		1	1	0.033
C _{max} (mcg/mL)	trandolapril	ND	0.05	0.002
	trandolaprilat	1.02	0.28	0.003
T _{max} (hr)	trandolapril	ND	0.77	0.5
	trandolaprilat	0.14	0.72	6
AUC (mcg·hr/mL)	trandolapril	ND	0.055	0.002
	trandolaprilat	0.47	0.46	0.046
T _{1/2} (hr)	trandolapril	ND	0.6	0.7
	trandolaprilat	6	1.6	3.5
% Bioavailability	trandolapril	ND	19	7.5
	trandolaprilat	37	43	40-60
% Elimination	bile	36	39	ND
	urine	18	16	33
	feces	36	40	66

TOXICOLOGY

Acute Toxicity

Table 12 summarizes the species-specific LD50 values for both oral and intraperitoneal administrations of trandolapril.

Table 12. Species-Specific LD50 Values for Both Oral and Intraperitoneal Administrations of Trandolapril

Routes	Species	Sex	LD ₅₀ (mg/kg)
Oral	Mouse	Male	4 875
		Female	3 990
	Rat	Male	> 5 000
		Female	> 5 000
Intraperitoneal	Mouse	Male	1 285
		Female	1 330
	Rat	Male	1 420
		Female	1 435

The symptoms observed in mice were: slight hypotonicity, pilo-erection, hunched back, motor incoordination, lethargy, locomotion difficulties and tremors. Deaths occurred within 48 hours after intraperitoneal administration and 3 hours after oral administration. Residual signs of

toxicity persisted for a maximum of 3 days. On autopsy macroscopic examination revealed lesions of the liver, lungs and gastrointestinal tract. In rats, pilo-erection and epistaxis were the main clinical signs of toxicity after oral administration. After intraperitoneal administration clinical signs were similar to those found in mice. Autopsy findings included: lung congestion, hemorrhagic appearance of pancreas and internal wall of abdominal cavity, deformation of lobes of liver and hypertrophy of spleen and kidneys. A dose of 200 mg/kg in the dog caused the death of 2/4 animals, 24 hours after administration. Hypotonicity, hypomobility, dehydration and respiratory difficulties were observed in the surviving animals. Autopsy revealed hemorrhagic thymus lesions of the liver, lungs and gastrointestinal tract.

Chronic Toxicity

Table 13 summarizes the chronic toxicity results for oral administrations of trandolapril in animals.

Table 13. Summary of Chronic Toxicity Results of Oral Administrations of Trandolapril in Animals

Species	Duration	No. of animals per group	Route	Dose (mg/kg/day)	Effects
Rat Sprague Dawley	30 days	10 M, 10 F	Oral	0, 4, 20, 100	At all doses: Retardation of body weight gain, decrease in heart weight and gastric ulceration. At 20 and 100 mg/kg/day: Increase in magnesium and blood urea.
Rat Sprague Dawley	6 months	60 M, 60 F	Oral	0, 0.25, 2.5, 25	At all doses: Growth retardation, polyuria and polydipsia. At 2.5 and 25 mg/kg/day: Indications of glomerulonephritis were seen histologically particularly in males, which correlated with observed changes in serum magnesium urea and creatinine.
Rat Sprague Dawley	18 months	50 M, 50 F	Oral	0, 0.25, 1.5, 9	At 9 mg/kg: Water consumption, magnesium and urea increased. At 1.5 and 9 mg/kg: A decrease in sodium was noted. At 0.25 and 1.5 mg/kg in the males and at 9 mg/kg in females: Decrease in erythrocytes.
Dog Beagle	30 days	3 M, 3 F	Oral	0, 10, 50, 250	At all doses: Increase in urinary volume for females and microscopic renal lesions in all animals. At 250 mg/kg: Increase in serum alkaline phosphatase for males; increase in urea for all doses in females and at 50 and 250 mg/kg for males.

Species	Duration	No. of animals per group	Route	Dose (mg/kg/day)	Effects
Dog Beagle	6 months	9 M, 9 F	Oral	0, 2.5, 25, 125, 250	At all doses: Decreased excretion of sodium, potassium, chloride, calcium, magnesium and urea. At 250 and 125 mg/kg: digestive signs of toxicity accompanied by hypotonicity and dehydration resulted in death and premature sacrifice. Ulcerative inflammatory lesions of the gastric and duodenal mucosa, and renal lesions. Esophageal inflammatory lesions were also seen. At 25 mg/kg: Anemia, increase in frequency of renal lesions in the female.
Dog Beagle	12 months	6 M, 6 F	Oral	0, 0.25, 2.5, 25	At 0.25 mg/kg: Weight decrease in 3 animals between weeks 24-49. Decreases in spleen, kidney and testes weights in males. At 25 mg/kg: Increase in α_2 globulin in males. Decreases in absolute brain weights in males.

Mutagenicity and Carcinogenicity

Trandolapril was not mutagenic in the Ames microbial mutagen test, the gene conversion test with *S. cerevisiae*, and in V79 cells. Detection of chromosomal aberrations in human lymphocytes and in Chinese hamster CHO cells as well as the micronucleus test in mice were all negative.

There was no evidence of a carcinogenic effect when trandolapril was administered by gavage for 18 months to male and female CDI mice at doses ≤ 25 mg/kg/day or to male and female Sprague Dawley rats at doses ≤ 8 mg/kg/day.

Reproduction and Teratology

Table 14 summarizes the reproduction and teratology results following administrations of trandolapril in animals.

Table 14. Reproduction and Teratology Results Following Administrations of Trandolapril in Animals

Species	No. of animals per group	Dose (mg/kg/day)	Duration of dosing	Results
Rat (Sprague Dawley)	30 M, 30 F	0, 1, 10, 100	M: 60 days before mating F: 14 days before mating to day 30 of gestation	At 10 and 100 mg/kg/day: Fetuses showed dilated ureters and increased renal pelvic cavitation
Rat (Sprague Dawley)	24 F	0, 100, 300, 1000	Days 6-15 of gestation	Dilatation of renal pelvis and ureters at 1000 mg/kg/day.
Rabbit (New Zealand White)	21 F	0, 0.2, 0.4, 0.8	Days 6-18 of gestation	At 0.8 mg/kg: Associated with maternal toxicity and severe effects on physical conditions of survivors, pre and post implantation losses were increased. Some fetuses had multiple malformations of the skull, oral cavity, heart vessels, etc. At 0.4 mg/kg: Deterioration in maternal condition, no consistent treatment-related effects on fetal development.
Rabbit (HYLA)	15 F	0, 0.1, 0.2, 0.4, 0.8	Days 6-18 of gestation	At 0.4 and 0.8 mg/kg: Weight loss, tremors, diarrhea and death, dilation of renal pelvis. At 0.1 and 0.2 mg/kg: Increased rate of fetal losses, dilation of renal pelvis.
Monkey (Cynomolgus)	6 F	0, 50, 250	Days 20-50 of gestation	At all doses: No sign of teratogenesis.
Monkey (Cynomolgus)	10 F	0, 5, 25, 125	Days 20-50 of gestation	At all doses: Slight decrease in body weight. No treatment related malformations. At 5 and 25 mg/kg: 4 abortions At 125 mg/kg: 7 abortions

REFERENCES

1. Bevan EG, et al. Effect of Renal Function on the Pharmacokinetics and Pharmacodynamics of Trandolapril. *Brit J Pharmacol* 1992;33 (2): 237p.
2. Brown NL, et al. Angiotensin-converting Enzyme Inhibition, Antihypertensive Activity and Hemodynamic Profile of Trandolapril (RU44570). *Eur J Pharmacol* 1988;148:79-91.
3. Chevillard C, et al. Cardiovascular Actions and Tissue-converting Enzyme Inhibitory Effects of Chronic Enalapril and Trandolapril Treatment of Spontaneously Hypertensive Rats. *J Cardiovasc Pharmacol* 1989;14:297-301.
4. Conen H, et al. Pharmacologic Profile of Trandolapril, a New Angiotensin-converting Enzyme Inhibitor. *Am Hear J* 1993;125:1525-1531.
5. De Ponti F, et al. Pharmacological Activity and Safety of Trandolapril (RU 44570) in Healthy Volunteers. *Eur J Clin Pharmacol* 1991; 40:149-153.
6. Dutrey-Dupagne C, et al. Effects of the Converting Enzyme Inhibitor Trandolapril on Short-term Variability of Blood Pressure in Essential Hypertension. *Clin Auton Res* 1991; 1:303-307.
7. Gaillard CA, Leeuw PW. Clinical Experiences with Trandolapril. *Am Heart J* 1993; 125:1542-1546.
8. Guidicelli JF, et al. Angiotensin-converting Enzyme Inhibition: Systemic and Regional Hemodynamics in Rats and Humans. *Am J Hypertens* 1991; 4:258S-262S.
9. Køber L, et al. A Clinical Trial of the Angiotensin-converting-Enzyme Inhibition Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction. *N.E. J Med* 1995; 333(25):1671-1676.
10. Mancia G, et al. Evaluation of the Antihypertensive Effect of Once-a-day Trandolapril by 24-hour Ambulatory Blood Pressure Monitoring. *Am J Cardiol* 1992; 70:60D-66D.
11. Nguyen Cong Duc L, Brunner HR. Trandolapril in Hypertension: Overview of a New Angiotensin-converting Enzyme Inhibitor. *Am J Cardiol* 1992; 70:27D-34D.
12. Patat A, et al. Safety and Tolerance of Single Oral Doses of Trandolapril (RU44570), a New Angiotensin-converting Enzyme Inhibitor. *Eur J Clin Pharmacol* 1989; 36:17-23.

PART III: CONSUMER INFORMATION

Pr MAVIK® Trandolapril Capsules

Read this carefully before you start taking MAVIK® and each time you get a refill. This leaflet is a summary and will not tell you everything about MAVIK®. Talk to your doctor, nurse, or pharmacist about your medical condition and treatment and ask if there is any new information about MAVIK®.

ABOUT THIS MEDICATION

What the medication is used for:

MAVIK® is used to treat:

- High blood pressure.
- Patients after a heart attack.

Managing your lifestyle:

The "lifestyle" part of your treatment is as important as your medication. In collaboration with your doctor, you can help reduce the risk of high blood pressure complications to maintain the lifestyle you are accustomed to. To do this, your doctor may discuss changes to your alcohol consumption and your diet. Your doctor will also probably recommend regular exercise and to completely avoid smoking.

What it does:

MAVIK® is an angiotensin converting enzyme (ACE) inhibitor. You can recognize ACE inhibitors because their medicinal ingredient ends in '-PRIL'.

This medicine does not cure your disease. It helps to control it. Therefore, it is important to continue taking MAVIK® regularly even if you feel fine.

Although you may not feel any symptoms for years, high blood pressure can lead to stroke, heart attack, kidney disease and other serious conditions.

Hypertension is the medical term for high blood pressure. When blood flows through the blood vessels it pushes against their walls, almost like water pushing against the sides of a hose. Blood pressure is like that "push". When blood pressure is high (like the water pressure in a hose when the nozzle is partially shut), damage can occur to the heart and blood vessels.

When it should not be used:

Do not take MAVIK® if you:

- Are allergic to trandolapril or any non-medicinal ingredients.
- Have experienced an allergic reaction (angioedema) with swelling of the hands, feet, or ankles, face, lips, tongue, throat,

- or sudden difficulty breathing or swallowing, to any ACE inhibitor or without a known cause. Be sure to tell your doctor, nurse, or pharmacist that this has happened to you.
- Have been diagnosed with hereditary angioedema: an increased risk of getting an allergic reaction that is passed down through families. This can be triggered by different factors, such as surgery, flu, or dental procedures.
- Are taking Entresto® (sacubitril/valsartan), due to the increased risk of serious allergic reaction which causes swelling of the face or throat (angioedema) when taken with MAVIK®. You must wait at least 36 hours after your last dose of sacubitril/valsartan before taking MAVIK®.
- Are already taking a blood pressure-lowering medicine that contains aliskiren (such as Rasilez®), or an angiotensin receptor blocker (ARB) which is another medicine to treat your high blood pressure [you can recognize ARBs because their medicinal ingredient ends in "-SARTAN".]; or another ACE inhibitor **and** you have one of the following conditions:
 - diabetes;
 - kidney disease;
 - high potassium levels;
 - heart failure combined with low blood pressure.
- Have narrowing of the arteries to one or both kidneys (renal artery stenosis).
- Have hypotension (low blood pressure).
- Are pregnant or intend to become pregnant. Taking MAVIK® during pregnancy can cause injury and even death to your baby.
- Are breastfeeding. MAVIK® passes into breast milk.
- Have one of the following rare hereditary diseases:
 - Galactose intolerance
 - Lapp lactase deficiency
 - Glucose-galactose malabsorption
 Because lactose is a non-medicinal ingredient in MAVIK®.

What the medicinal ingredient is:

Trandolapril

What the non-medicinal ingredients are:

Erythrosine, gelatin, iron oxides and hydroxides, lactose, maize starch, povidone, sodium lauryl sulphate, sodium stearyl fumarate, titanium dioxide.

What dosage forms it comes in:

Capsules: 0.5 mg, 1 mg, 2 mg, and 4 mg.

WARNINGS AND PRECAUTIONS**Serious Warnings and Precautions -Pregnancy**

MAVIK® should not be used during pregnancy. If you discover that you are pregnant or you are planning to become pregnant while taking MAVIK®, stop the medication and contact your doctor, nurse, or pharmacist as soon as possible.

BEFORE you use MAVIK® talk to your doctor, nurse or pharmacist if you:

- Are taking salt substitutes or foods containing potassium, potassium supplements, or a potassium-sparing diuretic (a specific kind of “water pill”).
- Have diabetes, liver or kidney disease.
- Have narrowing of an artery or heart valve disease.
- Have had a heart attack or stroke.
- Have heart failure.
- Are on dialysis or LDL apheresis (a treatment to remove LDL cholesterol from the blood).
- Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.
- Are possibly allergic to MAVIK® (or any drug used to lower blood pressure), including any of its non-medicinal ingredients. (Refer to the subheading “**What the non-medicinal ingredients are**” for a complete listing).
- Have recently received or are planning to get allergy shots for bee or wasp stings.
- Are on a low-salt diet.
- Are taking a medicine that contains aliskiren, such as Rasilez®, used to lower high blood pressure. The combination with MAVIK® is not recommended.
- Are taking an angiotensin receptor blocker (ARB). You can recognize an ARB because its medicinal ingredient ends in “-SARTAN”. The combination with MAVIK® is not recommended.
- Are taking an antibiotic containing trimethoprim and sulfamethoxazole.
- Are taking any of the following medicines, the risk of angioedema may be increased:
 - Medicines used to prevent organ transplant rejection (e.g. sirolimus) and for cancer (e.g. everolimus and temsirolimus).
 - Sitagliptin or other gliptins (to treat Type II diabetes)
 - neutral endopeptidase (NEP) inhibitors.
- Are receiving gold (sodium aurothiomalate) injections.
- Are less than 18 years old.
- Have lupus or scleroderma.

You may become sensitive to the sun while taking MAVIK®. Exposure to sunlight should be minimized until you know how you respond.

If you are going to have surgery and will be given an anesthetic, be sure to tell your doctor or dentist that you are taking MAVIK®.

Driving and using machines: Before you perform tasks which may require special attention, wait until you know how you respond to MAVIK®. Dizziness, lightheadedness, or fainting can especially occur after the first dose and when the dose is increased.

INTERACTIONS WITH THIS MEDICATION

As with most medicines, interactions with other drugs are possible. Tell your doctor, nurse, or pharmacist about all the medicines you take, including drugs prescribed by other doctors, vitamins, minerals, natural supplements, or alternative medicines.

The following may interact with MAVIK®:

- Agents increasing serum potassium, such as a salt substitute that contains potassium, potassium supplements, a potassium-sparing diuretic (a specific kind of “water pill”; examples include spironolactone, triamterene or amiloride) or co-trimoxazole (trimethoprim/ sulfamethoxazole); cyclosporine, an immunosuppressant medicine used to prevent organ transplant rejection; and heparin, a medicine used to thin blood to prevent clots;
- Alcohol. It may cause low blood pressure, dizziness and fainting;
- Allopurinol, used to treat gout;
- Antacids;
- Antidepressants, used to control your depression;
- Antidiabetic agents, including insulin and oral medicines used to control your blood glucose;
- Bee or wasp venom found in allergy shots for bee or wasp stings;
- Blood pressure-lowering drugs, including diuretics (“water pills”, e.g., hydrochlorothiazide), aliskiren-containing products (e.g. Rasilez®), or angiotensin receptor blockers (ARBs);
- Corticosteroids used to treat joint pain and swelling;
- Cytostatic agents used to treat cancers;
- Dextran sulphate used in low density lipoprotein apheresis to remove cholesterol from the blood;
- Digoxin used to treat irregular heartbeats;
- Gold for the treatment of rheumatoid arthritis;
- Immunosuppressive agents used to prevent rejection of a transplanted organ or treat autoimmune diseases;
- Inhalation anesthetics;
- mTOR (mammalian target of rapamycin) inhibitor therapy used to lower the body’s ability to reject a transplant (e.g. sirolimus) or to treat certain types of cancer (e.g. temsirolimus, everolimus);
- Lithium used to treat bipolar disease;
- Nifedipine SR used to treat chest pain or lower blood pressure;
- Non-steroidal anti-inflammatory drugs (NSAIDs) used to reduce pain and swelling. Examples include ibuprofen, naproxen, celecoxib, and acetylsalicylic acid (aspirin) used in higher doses;

- Procainamide used to treat irregular heartbeats;
- Co-trimoxazole (trimethoprim/sulfamethoxazole);
- Neutral endopeptidase (NEP) inhibitors.

PROPER USE OF THIS MEDICATION

Usual Adult Dose:

Take MAVIK® exactly as prescribed. Dosage must be individualized. The recommended initial dose of MAVIK® is 1 mg once daily. The dose can be increased over time by your doctor, up to a maximum dose of 4 mg once daily. For patients with kidney or liver impairment, the recommended initial dose is 0.5 mg once daily.

It is recommended to take your dose at about the same time every day. You can take MAVIK® with a meal, or if you prefer, on an empty stomach.

With your first dose of MAVIK® your blood pressure may drop too low and you may experience a sensation of lightheadedness. This effect should disappear once your system becomes used to MAVIK®. If this effect persists, discuss this with your doctor. Your medication may need to have the dose reduced or changed.

Overdose:

If you think you (or someone you know) may have taken too much MAVIK®, contact your doctor, nurse, pharmacist, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms. Tell them how much you have taken and show them the capsules.

Overdose symptoms expected with drugs like MAVIK® include a severe drop in blood pressure, shock, stupor, and an abnormally slow heart beat.

Missed Dose:

If you forget to take your dose of MAVIK®, take it as soon as you remember, if you remember on the same day. If not, do not take your missed dose at all. Simply wait until it is time for your next dose. Do not double dose.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Like all medicines, MAVIK® can cause side effects. After you have started taking MAVIK®, it is important that you tell your doctor at once about any unexplained symptom you might experience.

Frequent side effects include coughing and dizziness. Other occasional side effects include:

- Headache
- Flu-like symptoms such as sore throat, fever, malaise, muscle pain or weakness
- Rash
- Nausea, vomiting, diarrhea, abdominal pain, loss of appetite (anorexia)
- Fatigue
- Sensation of lightheadedness, confusion
- Sad mood (depression)
- Blurred vision
- Confusion
- Dermatitis
- Sinusitis and rhinitis

If any of these affects you severely, tell your doctor, nurse or pharmacist.

MAVIK® can cause abnormal blood test results. Your doctor will decide when to perform blood tests and will interpret the results.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM				
Symptom/effect		Talk with your doctor or pharmacist		Stop taking drug and seek immediate emergency medical attention
		Only if severe	In all cases	
Common	Hypersensitivity reactions Skin rash, skin eruption or other effect of the skin or eyes, itching or fever			✓
	Low blood pressure Fainting, dizziness, lightheadedness, may occur when you go from lying or sitting to standing up.	✓		
	Increased levels of potassium in the blood: Irregular or skipped heart beats, muscle weakness and generally feeling unwell		✓	
Uncommon	Allergic Reactions (angioedema) Swollen mouth, lips, tongue, eyes, extremities, throat or difficulty swallowing or breathing			✓

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Symptom/effect	Talk with your doctor or pharmacist		Stop taking drug and seek immediate emergency medical attention
	Only if severe	In all cases	
Intestinal angioedema Abdominal pain that may become more severe after eating, nausea, vomiting, intestinal cramps			✓
Kidney Disorder: change in frequency of urination, nausea, vomiting, swelling of extremities, fatigue		✓	
Jaundice (Liver Disorder) Yellowing of the eyes and skin, dark urine, abdominal pain, nausea, vomiting, loss of appetite			✓
Electrolyte Imbalance: weakness, drowsiness, muscle pain or cramps, irregular heartbeat		✓	
Rare	Decreased Platelets: bruising, bleeding, fatigue and weakness		✓
	Decreased White Blood Cells: infections, fatigue, fever, aches, pains, and flu-like symptoms		✓
Unknown	Toxic Epidermal Necrolysis: Severe skin peeling, especially in mouth and eyes		✓
	Stevens-Johnson Syndrome: Blistering of the mucous membranes of the skin including mouth, lips, eyelids, and genitals		✓

This is not a complete list of side effects. For any unexpected effects while taking MAVIK®, contact your doctor, nurse, or pharmacist.

HOW TO STORE IT

Store MAVIK® between 15° and 25°C in original container. MAVIK® should not be stored beyond the date indicated on the container. **Keep this drug out of reach and sight of children.**

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on [Adverse Reaction Reporting \(https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html\)](https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

The most recent version of this document plus the full Product Monograph, prepared for health professionals can be found at:

www.mylan.ca

or by contacting the sponsor, BGP Pharma ULC, Etobicoke, Ontario, M8Z 2S6 at:
1-844-596-9526

This leaflet was prepared by BGP Pharma ULC.

Last revised: September 16, 2019

Entresto® and Rasilez® are products of Novartis Pharmaceuticals Canada Inc.